Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK discusses the result of the RAMES study (NCT03560973) which was evaluating the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in relapsed mesothelioma patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.